WSA delivered 2% organic growth and improved profitability in the 2025/26 financial year
18.11.2026 07:30:00 CET | WSA A/S | Press release

Lynge, Denmark – November 18, 2026 – WSA, a leading hearing healthcare group, today announced results for the financial year 2025/26 (October 1, 2025 - September 30, 2026), showing organic revenue growth of 2%, and an EBITDA margin improvement of 1%-point, in line with the guidance.
Jan Mäkelä, CEO of WSA, says:
In the financial year 2025/26, we remained disciplined in executing our strategy and advancing innovation in personalized hearing care, and on driving profitability. We delivered 2% organic revenue growth and improved the profit margin in line with our guidance. Our consumer-facing businesses performed strongly, while the timing of product launches impacted our wholesale business.
At WSA, we believe that better hearing starts with recognizing that no two people hear the world in the same way. Understanding individual sound preferences opens up a new dimension in personalized hearing care. We have brought this approach to life through several significant innovations and product launches, which have been very well received in the market.
Our outlook for 2026/27 is impacted by the non-renewal of a large US managed care contract, as previously announced. Excluding this impact, we expect revenue to grow in line with or above the market, with continued improvement in profitability. Although the non-renewal of the contract weighs on our near-term guidance, our disciplined strategy execution and competitive product portfolio provide a solid foundation for long-term profitable growth.
Highlights FY 2025/2026 (FY last financial year in brackets)
- WSA Group delivered organic revenue growth of +2% (0%) to EUR 2,535 million. Group reported revenue was -2%.
- The Wholesale business delivered organic growth of -3%, impacted by the timing of WSA’s product launches. Growth momentum improved toward the end of the year.
- The Consumer-facing business delivered +7% organic growth driven by Managed Care, Retail and Online businesses.
- Revenue growth was mixed across geographies with +3% organic growth in Americas, 0% organic growth in EMEA, and 0% organic growth in APAC.
- EBITDA before special items increased to EUR 473 million (EUR 456 million).
- EBITDA margin before special items increased to +18.7%, an improvement of 1.0%-point compared with last year, in line with our guidance.
- WSA launched Signia MaX, the world's first AI hearing aid platform with four Deep Neural Networks, designed to help wearers stay connected in complex and noisy listening environments, and Widex Allure AI with Clarity Boost, which combines Widex’ natural everyday sound with on-demand AI-powered support for clearer conversations in noisy environments.
- WSA announced changes to its Board of Directors. Adam Westemann, co-owner and board member of T&W Medical is stepping down as Vice Chair of the board. Julian Tøpholm, co-owner and board member of T&W Medical, is becoming the new Vice Chair, representing the Tøpholm and Westermann families.
Highlights Q4 FY 2025/26 (Q4 last financial year in brackets)
- In Q4, WSA delivered organic revenue growth of 4% (-1%) to EUR 654 million. Group reported revenue increased 5% due to currency tailwinds.
- EBITDA before special items was EUR 126 million with a margin improvement of 0.1%-points.
- The Wholesale business delivered 0% organic growth in Q4, impacted by the timing of WSA’s product launches.
- In Q4, the Consumer-facing business delivered +8% organic growth driven by Managed Care, Retail and Online businesses.
- Revenue growth was mixed across geographies in Q4 with +5% organic growth in Americas, +3% organic growth in EMEA, and +1% organic growth in APAC.
Outlook Financial year 2026/2027
For the financial year 2026/27, WSA expects -2 to +2% organic revenue growth. The EBITDA margin (before special items) is expected to decline by around 2%-points versus financial year 2025/26 (18.7%).
The outlook is based on the following key assumptions:
The volume growth in the hearing aid market is expected to be in the range of 3-4%. Some volatility is expected due to the ongoing uncertain macroeconomic environment.
The revenue growth outlook is supported by WSA’s competitive product portfolio, including the recent launches of Signia Max and Widex Allure AI and the launch of additional form factors.
In August 2026, WSA announced that a contract with a large US Managed Care customer will not be renewed after it expires on January 1, 2027. This is now estimated to have an impact of around 5%-pts on group revenue growth and around 3%-pts on group margin for FY2026/27. Excluding this impact, WSA expects revenue growth in line with or above the market and continued improved profitability.
The EBITDA margin outlook is supported by cost reductions made in FY 2025/26 as well as ongoing optimization and prudent cost management.
For the full FY 2025/26 Annual Report, please go to WSA.com/investors/reports

Contacts
Henning Klemmesen
Tel:+45 20 66 66 89Investor.relations@wsa.comUlla LundhusWSA Corporate Communications
Tel:+45 5319 4767ulla.lundhus@wsa.comDocuments
Alternative languages
Subscribe to releases from WSA A/S
Subscribe to all the latest releases from WSA A/S by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from WSA A/S
Widex Allure AI RIC with Clarity Boost Now Available in the U.S. and Major European Countries, Redefining How AI Supports Natural Hearing14.10.2026 10:19:49 CEST | Press release
Expansion into 15 additional countries brings Widex natural sound and on-demand AI support to more wearers worldwide 5x more wearers preferred Allure AI RIC with Clarity Boost over key competitors with AI-based denoising in real world listening situations1; Clarity Boost delivers up to 20% better speech understanding in conversations.2 Latest Widex Compass Cloud release reintroduces Zen Therapy, making personalized tinnitus support easier to deliver and incorporate into everyday life LYNGE, DENMARK, October 14, 2026 – Widex, the leading brand in natural sound and part of WSA, today announced the availability of Widex Allure AI RIC with Clarity Boost in 15 additional countries, including the U.S. and major European markets. Building on strong demand and positive feedback from hearing care professionals, the expansion brings Widex’s unique approach to artificial intelligence to more wearers worldwide – preserving Widex’s signature natural sound for everyday listening while giving wearers
New WSA Clinical Studies Link Sound Preference to Higher Hearing Aid Conversion12.10.2026 14:33:03 CEST | Press release
Studies across 42 clinics in three countries found conversion was 5 percentage points higher when individual sound preferences were explored, reinforcing the value of helping patients compare distinct sound designs and identify what sounds right to them LYNGE, Denmark – October 12, 2026 – WSA, a leading hearing healthcare group, today announced new clinical study results showing that hearing aid conversion rates were 5 percentage points higher when individual sound preferences were systematically explored during consultations. Conducted across 42 clinics in Spain, Canada, and the US, the studies found that the approach was associated with a greater likelihood of clients purchasing hearing aids. The findings build on the April launch of WSA Sound Preference, a global program that introduced research and clinical tools to help hearing care professionals understand how individual sound preferences influence hearing aid experiences. The new studies demonstrate the practical value of bringi
Nye kliniske studier fra WSA forbinder lydpræferencer med højere konvertering til høreapparater12.10.2026 14:33:03 CEST | Pressemeddelelse
Undersøgelser foretaget på 42 klinikker i tre lande viste, at konverteringsraten var 5 procentpoint højere, når der blev taget højde for individuelle lydpræferencer, hvilket understreger værdien af at hjælpe patienterne med at sammenligne forskellige lyddesign og finde frem til, hvad der lyder rigtigt for dem LYNGE, Danmark – 12. oktober 2026 – WSA, en førende koncern inden for hørepleje, offentliggjorde i dag resultaterne af nye kliniske undersøgelser, der viser, at konverteringsraten for høreapparater var 5 procentpoint højere, når individuelle lydpræferencer blev systematisk undersøgt under konsultationerne. Undersøgelserne, der blev gennemført på 42 klinikker på tværs af Spanien, Canada og USA, viste, at denne tilgang var forbundet med en større sandsynlighed for, at kunderne købte høreapparater. Resultaterne bygger videre på lanceringen i april af WSA Sound Preference, et globalt program, der introducerede forsknings- og kliniske værktøjer til at hjælpe hørespecialister med at for
WSA udnævner Peter Bøggild til ny CFO16.9.2026 12:02:00 CEST | Pressemeddelelse
Lynge, Danmark – 16. september 2026 – WSA, en førende høreapperatkoncern, meddeler i dag, at Peter Bøggild er blevet udnævnt til ny CFO og medlem af direktionen og ledelsen. Peter Bøggild efterfølger Marianne Wiinholt, der trådte tilbage i slutningen af august for at påtage sig en række bestyrelses- og rådgivningsopgaver. Peter Bøggild tiltræder hos WSA senest den 1. december 2026. Peter kommer til WSA fra Novo, hvor han i mere end 21 år har haft flere ledende stillinger inden for Finance, senest som Senior Vice President for Business Finance og Group Vice President for R&D Performance, Finance & Governance. Jan Mäkelä, CEO for WSA, siger: ”Jeg er glad for at byde Peter Bøggild velkommen til WSA, hvor han vil spille en central rolle i gennemførelsen af vores strategi om at bringe innovation og personlig hørepleje ud til flere mennesker verden over. Han bringer værdifuld og bred erfaring inden for økonomi, strategi og ledelse fra life science-industrien med sig til WSA. Jeg ser frem til
WSA delivered 3% organic growth and improved profitability in the third quarter of FY 2025/2625.8.2026 07:30:00 CEST | Press release
Lynge, Denmark – August 25, 2026 – WSA, a leading pure-play hearing healthcare group, today announced results for the third quarter of the financial year 2025/26 (April 1, 2026 – June 30, 2026) showing 3% organic revenue growth and an EBITDA margin improvement of 2%-points to 19.1%. The outlook for FY 2025/26 is confirmed and narrowed.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom